TriangleNCT01672736 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- LTE60
- restrictive Agreement
- true
- limitations And Caveats
- description
- Patient enrollment was stopped prematurely due to the drug manufacturer's decision to terminate the development of the study drug, Linsitinib. The study did not proceed to Phase II portion of the study protocol.
- point Of Contact
- Suzanne.Trudel@uhn.ca
- organization
- University Health Network - Princess Margaret Cancer Centre
- phone
- 416-946-4501
- phone Ext
- 4566
- title
- Dr. Suzanne Trudel
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- LTE60
- restrictive Agreement
- true
- limitations And Caveats
- description
- Patient enrollment was stopped prematurely due to the drug manufacturer's decision to terminate the development of the study drug, Linsitinib. The study did not proceed to Phase II portion of the study protocol.
- point Of Contact
- Suzanne.Trudel@uhn.ca
- organization
- University Health Network - Princess Margaret Cancer Centre
- phone
- 416-946-4501
- phone Ext
- 4566
- title
- Dr. Suzanne Trudel
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice